Pharmaceuticals 2024 - Recent Advances in Pharmaceutical Sciences Towards a Healthy Life
Pharmaceuticals 2024 - Recent Advances in Pharmaceutical Sciences Towards a Healthy Life
The 20th Anniversary
pharmaceuticals, Nucleic Acids-based platforms, Neurodegeneration, Pain, Infection, Immunity and Inflammation, Bioorganic molecules, Drug design
Welcome from the Chairs
We are very pleased to announce that a ceremony is also planned to honor Prof. Jean Jacques Vanden Eynde, former Editor in Chief of Pharmaceuticals (2015-2022), in recognition of his years-long dedication to Pharmaceuticals.
Please receive our warmest invitation to join us in Barcelona from the 27th to the 29th of November this year!
Prof. Dr. Amelia Rauter, Dr. Alfredo Berzal Herranz, and Prof. Dr. Mary Jane Meegan
Pharmaceuticals 2024 Chairs
Follow the conversation on Twitter/X with #Pharmaceuticals2024
Conference Secretariat
Dr. Ana Sanchis
Ms. Raquel Sellés
Dr. Elena González
Email: pharmaceuticals2024@mdpi.com
Pharmaceuticals 2024 - Thank you for your participation!
For more photos and moments of the conference please visit our Gallery!
Pharmaceuticals 20th Anniversary
20th Anniversary of Pharmaceuticals Video
Event Chairs
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Portugal
Prof. Dr. Amélia Pilar Rauter, a full professor, was the founder of the Portuguese Society of Chemistry Carbohydrate Chemistry Group in 1992, and the founder (2001) and leader of the CQB Carbohydrate Chemistry Group—FCUL, a center of excellence of the ESF network Euroglycoforum (2009–2014), and Executive of its Interest Group Glycochemistry. Presently, she is the leader of the CQE Carbohydrate Chemistry Group. Her scientific interests are mainly within the area of organic and biomolecular chemistry. They cover the design and synthesis of new leads based on carbohydrate structures with new mechanisms of action, as well as the isolation and structure elucidation of active principles from plants/marine resources. This research led to the discovery of lead molecules for diabetes, degenerative diseases (Alzheimer´s and Prion diseases, cancer), and infection. Her research falls within the global objective of developing creative and sustainable chemistry for better health.
Department of Molecular Biology, Instituto de Parasitología y Biomedicina López-Neyra (IPBLN) CSIC, Spain
Alfredo Berzal-Herranz received his PhD in Molecular Biology from the Autonoma University of Madrid (1990). After a short stay in the Department of Microbiology, at the Uppsala University (Sweden), he moved to the Department of Microbiology, College of Medicine, University of Vermont (USA), as Postdoctoral Researcher. In 1993 he returned to Granada, Spain, joining the Instituto de Parasitologí¬a y Biomedicina López-Neyra (IPBLN) belonging to the Spanish National Research Council (CSIC), where he established his own research group and Chair the Department of Molecular Biology. Since April 1997 to November 2005, he was the Deputy Director of the IPBLN-CSIC and Director since November 2005 to March 2014. He has authored over 90 research articles and book chapters and edited 10 special research issues. He serves or has served as Editorial Board Member of more than 15 research journals. His group is currently interested in understanding the structure/function relationship of viral RNA genomes. Pursuing the identification of the molecular mechanisms used by the RNA viruses to store all necessary genetic information and studying the potential use of genomic structural RNA domains as potential antiviral targets. Further, his group is interested in the design and characterization of antiviral RNA molecules.
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Ireland
Mary J Meegan completed her PhD degree in UCD under the direction of Professor Dervilla Donnelly in the area of natural product chemistry and subsequently carried out postdoctoral research at the University Chemical Laboratory, Cambridge University in the research group of Professor Alan Battersby in the area of porphyrin synthesis and biosynthesis. Following further research periods at University College Dubin and CNRS Gif-sur-Yvette, she was appointed as lecturer in Pharmaceutical Chemistry at the School of Pharmacy and Pharmaceutical Sciences in Trinity College Dublin. She has research experience in the School of Pharmacy and and Pharmaceutical Sciences, Trinity College in the general area of pharmaceutical and medicinal chemistry, with over 100 peer-reviewed scientific papers covering topics such as design and synthesis of anticancer drugs, drug impurity profiling, synthetic methods for library design and in vitro screening. She has extensive experience in scientific and technical management having led an active research group, has acted as Head of the Department of Pharmaceutical Chemistry and as subject area head of Pharmaceutical Chemistry at the School of Pharmacy. Research collaborations have been established within Trinity College with Dr. Niamh O'Boyle (School of Pharmacy and Pharmaceutical Sciences), Dr D Zisterer, Dr D Fayne in the School of Biochemistry and Immunology and also with many European research centres. She is a member of several International Scientific Societies.
Event Committee
María-Jesús Pérez-Pérez is Research Professor at the Medicinal Chemistry Institute belonging to the Spanish National Research Council (IQM, CSIC) in Madrid (Spain). She has been Head of Department and Director of the above mentioned Institute. Her research is mostly devoted to antiviral and antitumor chemotherapy from a medicinal chemistry perspective. She has been working in selective inhibitors against therapeutically-relevant nucleoside processing enzymes (thymidine phosphorylase, nucleoside kinases, etc..) as well as in the design and synthesis of tubulin-binding agents. In the antiviral field, her work has involved the identification and optimization of antivirals against HIV and enterovirus, while her present lines of research are centered in alphavirus (i.e CHIKV) and flavivirus (i.e WNV), combining viral and host-approaches. She has been membered of the Board of Directors of the International Society for Antiviral (ISAR) and of the Spanish Society of Medicinal Chemistry (SEQT)
Centro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Portugal
M. Matilde Marques holds BS and PhD degrees in chemical engineering and a Habilitation title (D.Sc.) in chemistry from Instituto Superior Técnico (IST), University of Lisbon, Portugal. She is currently a full professor at IST, where she teaches organic and medicinal chemistry, and vice-chair of IST’s Scientific Council. Her research focuses on the mechanisms of toxicity induced by environmental and therapeutic xenobiotics, on the development/validation of analytical methodologies for the detection and quantitation of biomarkers of exposure to toxic agents, with emphasis on MS-based methodologies, and on the design, synthesis, and biological evaluation of potential therapeutic agents. She has chaired the Division of Medicinal Chemistry of the Portuguese Chemical Society (2016-2020). She served (2008-2022) on the Editorial Advisory Board for Chemical Research in Toxicology, currently serves on the editorial board of Pharmaceuticals, and has been a member of multiple working groups for the International Agency for Research on Cancer.
Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Türkiye
Prof. Dr. Ilkay Erdogan Orhan holds a Pharmacist degree (1993) from Gazi University (Ankara, Türkiye), 1st M.Sc. degree from the Department of Pharmacognosy at the same Faculty in 1996 with a young scientist scholarship provided by the Scientific and Technological Research Council of Türkiye and 2nd M.Sc. degree in marine natural product chemistry (1998) at the University of the Ryukyus (Japan) with a Monbusho scholarship. She earned a Ph.D. in Pharmacognosy at the Faculty of Pharmacy, Gazi University (2022). She was the post-doc researcher at Department of Chemistry at the University of Winnipeg (Canada) in 2003 under the NATO-TUBITAK fellowship. She was promoted to Assoc. Prof. position in 2004 and promoted to full professor in 2009. Dr. Orhan was appointed as Dean of the Faculty of Pharmacy at Eastern Mediterranean University in Northern Cyprus (2011-2014) and Dean of the Faculty of Pharmacy at Gazi University (2016-2024). She is the author of more than 295 scientific papers listed by SCE, 47 articles in other scientific journals, 24 book chapters, 4 patents (Turkish, US, & EP), 6 patent applications, and 4 books. Her h index is 53 (Web of Science) and 58 (SCOPUS) with over 14500 citations.
Department of Environmental Biology, Sapienza University of Rome, Rome, Italy
Prof. Daniela De Vita is working in the field of extraction and isolation of bioactive compounds from plants and lichens, and their analysis by chromatographic and spectroscopic techniques. She is lecturer of Pharmaceutical Botany and Biology, and courses at the Doctoral Programs. She supervised Ph. D., M. Sc. and diploma theses. She is author of more than 70 publications in international journals and communications at national and international congresses.
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza del Rinascimento 6, Urbino Italy
ACADEMIC POSITIONS March 2015 – today. Associate professor (medicinal chemistry) November 1996 – February 2015. Assistant professor (medicinal chemistry) UNIVERSITY STUDIES PhD in Medicinal chemistry – Drug-chemical Department at the University of Bari Master’s Degree in Pharmacy – Faculty of Pharmacy at the University of Urbino RESEARCH FIELDS Design, synthesis, structure-activity relationships and pharmacological activity of molecules belonging to various classes of drugs, mainly those interacting with the endo-/paracannabinoid system (CB ligands, FAAH, MGL and NAAA inhibitors), anticancer and antiviral drugs, and glycolipid surfactants. The results, based on collaborations with international and national scientific groups, led also to both international patents and clinical trials. Papers and patents are available on the web page https://scholar.google.com/citations?user=LGrccH8AAAAJ&hl=en. REFEREE ACTIVITY International journals such as Archiv. Pharm., Bioorg. Med. Chem., Biochimie, ChemMedChem, Curr. Drug Targets, Curr. Top. Med. Chem., Drugs Drug Candidates, Eur. J. Med. Chem., Food Chem., Int. J. Mol. Sci., J. Med. Chem., Mar. Drugs, Molecules, Mol. Pharm.
Faculty of Medicine and Pharmacy, University of Mons, Belgium,
Faculty of Pharmacy, University of Brussels (ULB), Belgium
François Dufrasne graduated as a pharmacist at the Institute of Pharmacy of the ULB in 1996 and doctor of pharmaceutical sciences in 2002. He teaches the design, analysis and mechanism of action of organic drugs. His research focuses on the design and organic synthesis of molecules of therapeutic interest, with a predilection for those that treat cancer and bacterial infections. He is the author of 48 publications in international journals and 2 patents.
Our group uses patch clamp electrophysiology to investigate presynaptic mechanisms in synaptic transmission. In particular, we are interested in modulation of ion channels and G protein-coupled receptor in disease conditions, with work on pain, epilepsy and ataxia. We are also investigating the effect of psychedelic drugs in pain. We investigate molecular determinants of ion channel and receptor modulation in native neurones and recombinant cells and synaptic transmission in mammalian cerebellum and hippocampal brain slices. We have previously investigated plant derived cannabinoids as therapeutic agents.
Carmen Terán, PhD in Pharmacy from the University of Santiago de Compostela, is an Associated Professor of Organic Chemistry at the University of Vigo, Spain, where she is part of the management team of the Department of Organic Chemistry and academic coordinator of Master´s Degree in Chemical Investigation Research and Industrial Chemistry. She has done research stays at the "Istituto di Chimica Farmaceutica e Tecnica Farmaceutica, Universita degli Study of Perugia" and at the "Dipartimento di Scienze Farmaceutiche, Universita di Padova" (Italy) where get involved in different Medicinal Chemistry projects. She has participated in several projects and research contracts at the state or regional level and the University of Vigo being co-author of more than eighty scientific publications in journals indexed in the JCR, several congress communications and some book chapters and patents. Her current research is focused on the development of drugs of heterocyclic structure with potential application in aging-related disorders: Alzheimer´s and Parkinson´s diseases, cardiovascular disorders or cancer.
Foodborne Toxin Detection and Prevention Research Unit, Western Regional Research Center, USDA‐ARS, USA
Jong H. Kim investigates the development of new, highly effective intervention strategies for the control of fungal pathogens, including those producing mycotoxins. The prevention of fungal pathogens is often very difficult since potent antifungal agents for eliminating resistant pathogens are limited. To address this, he validated the use of safe natural products or their derivatives in debilitating fungal defense systems to environmental stressors, identifying fungal antioxidants or cell wall systems as the effective targets of natural products. He also identified multiple factors, such as differences in fungal physiology and species, ingredients in formulations, and the antioxidant and pro-oxidant potential of compounds, that can positively or negatively influence the antifungal or antimycotoxigenic activity of natural products. Dr. Kim’s expertise in antifungal chemosensitization as an intervention strategy is widely recognized by fellow researchers in academia and corporations.
Dr. Gunnar Dietz is senior lecturer (“Privatdozent”) for neurobiology) at Göttingen University Medical school, Germany, and Senior Manager Global Medical Affairs for one of the largest producers of phytopharmaceuticals. For more than the last 25 years, his major research interests have been in cognitive impairment, dementia, and neurodegenerative diseases, including Alzheimer’s disease, vascular dementia and Parkinson’s disease. Until 2012, her worked at H. Lundbeck A/S in Copenhagen in drug discovery for Parkinson’s and other brain diseases. He did his graduate studies at The Rockefeller University in New York, earning a Ph.D. in developmental neurobiology. Earlier, he studied biology at the Albertus-Magnus-Universität in Cologne, Germany, doing his lab work for his biology Diplom at the Max-Planck-Institute for breeding research.
Center for Neuroscience and Cell Biology (CNC-UC), Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra (UC), Portugal
C Pereira is Biochemist (1991), Master in Cell Biology (1994) and received, in 2000, a PhD in Cell Biology, UC, Portugal. Presently, she is Principal Investigator with tenure at the Fac. Medicine, UC, and leads a research line at the Cell Signaling and Metabolism group at CNC-UC aimed to clarify the biological basis of neurodegenerative disorders (Alzheimer disease) and mental illnesses (bipolar disorder and schizophrenia), focusing on the deregulation of cellular stress responses, namely on ER and mitochondria stress and the close ER-mitochondria contacts (MAMs), and to explore novel preventive and therapeutic strategies, especially of natural resources. To address these fundamental questions, both in vitro and in vivo experimental models, as well as human samples (blood are used. She published > 90 peer-reviewed articles, mainly in Q1 journals and the scientific impact of her research is reflected in the high number of citations (~5000) and the H index (39).
Dr Darren Fayne holds a PhD from Dublin City University (DCU) in computational and organic chemistry. He worked for two years at Solvay Pharmaceuticals in Hannover, Germany as a computer-aided drug designer from March 2003. In 2005 Dr Fayne joined the Molecular Design Group in Trinity College Dublin as a Senior Research Fellow. His research focus is the rational computational design of novel small molecular modulators of key disease related proteins. In 2024 he started as an Assistant Professor (above bar) in Computational Chemistry in DCU. In the late 2000’s, he co-founded and served as a director of a rational drug design campus spin-out company to commercialise intellectual property and develop compounds for the treatment of an orphan cancer – malignant pleural mesothelioma. A key aspect of his work forming a bridge between chemistry & biology and utilising computational design methodologies to collaboratively discovery novel small molecules with the potential to treat human disease. To date he has successfully filed two patents, published 49 articles in peer-reviewed journals and one book chapter.
NOVA Medical School - Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Portugal
Raffaella Gozzelino graduated at the University of Parma, Italy, in 2001. She obtained her Master and PhD degrees by the University of Lerida, in 2005 and 2007, respectively. In December 2007, she started her post-doctoral studies at the Gulbenkian Institute of Science, Portugal, where she became staff scientist in 2012. Since 2015, she is a Group Leader at NOVA Medical School, NOVA University of Lisbon, Portugal. In 2020, she was appointed as Rector of the Atlantic Technical University and Coordinator of the Sea Campus, in Cape Verde. In 2022, she became Executive Project Coordinator for West Africa by Parley Foundation for the Ocean Portugal, and in 2023 she founded Diáspora Mundi, joining qualified diaspora professionals to provide scientific services in Africa. Raffaella is also: international consultant (WHO); co-Chair of DOTCAN (NGO); Member of the Board of Director of BioIron; Member of 12 International Granting Agencies’ Reviewing Panels; External collaborator (CE3C-Faculty of Science, University of Lisbon); Invited Lecturer; and Academic Editor. Her research was published in 33 international peer-reviewed scientific articles.
A native of Philadelphia, PA, I received my BA in Biochemistry from the University of Pennsylvania, and my PhD in Genetics from the Hebrew University of Jerusalem. I then returned to Philadelphia to do postdoctoral research at the Children’s Hospital of Philadelphia, where I began to work on antimicrobial peptides. I was a faculty member at the University of Medicine and Dentistry of New Jersey (now part of Rutgers University) from 1993-2013, and the University of Florida from 2013-2019. Since then, I have been a professor in the Department of Oral Immunology and Infectious Diseases at the University of Louisville School of Dentistry, where I study innate immunity and the development of novel antimicrobial agents.
Dr Jóhannes Reynisson FRSC began his academic career at the University of Iceland where he read chemistry (BSc/MSc). His PhD was obtained from the University of Copenhagen in 2000; the research work was carried out at the Risø national laboratory (Denmark) and Georgia Institute of Technology (GA, USA). He spent two and a half years in Germany as a post-doctoral fellow at the Max-Planck-Institut für Strahlenchemie, Mülheim and the University of Leipzig. He worked for five years at the Institute of Cancer Research in London as a molecular modeller developing anticancer drug candidates followed by a lectureship at the Nottingham Trent University. For ten years, he was a senior lecturer in computational chemistry and molecular modelling at the University of Auckland, New Zealand. Now he is a lecturer in drug discovery at Keele University, United Kingdom.
Antonio Vassallo is a Professor in Technology, Socioeconomics and Regulation of Medicinal and Health and Wellbeing Products at the Department of Health Sciences, University of Basilicata, Potenza, Italy. His main field of research deals with studies of the formulation, preparation, and control of synthetic or biologically active compounds isolated from food and medicinal plants in conventional and innovative dosage forms. He isolated and characterized a large number of new natural compounds and evaluated the in vitro and in vivo biological activity of extracts and isolated compounds from studied plants.
Plenary Speakers
CIC bioGUNE, Bizkaia Technology Park, Spain,
Ikerbasque, Basque Foundation for Science, Spain
Breaking the limits in understanding glycan recognition by NMR
Jesús Jiménez-Barbero is Ikerbasque Research Professor and Scientific Director of CIC bioGUNE since 2014. He received his PhD in 1987. He later spent pre- and post-doc stages (1988-1992) at CERMAV-CNRS; Univ Zurich; National Institute for Medical Research, and Carnegie Mellon. Before moving to CIC bioGUNE where he has led its recognition as Severo Ochoa Center of Excellence in 2017 and 2022, he was CSIC Research Professor at CIB-CSIC (2002-14). Previously, he was CSIC tenured (1992-96) and senior scientist (1996-2002), and Visiting Professor at École Normale Supérieure (2004), Sorbonne (2009), Milano Bicocca (2009-12). Now at the University Basque Country since 2016.
https://www.cicbiogune.es/people/jjbarbero
Max Planck Institute of Colloids and Interfaces, Director. Department of Biomolecular Systems,
Free University Berlin, Professor. Institute of Chemistry and Biochemistry
Peter H. Seeberger, a chemist, was a tenured professor at MIT and ETH Zurich before becoming director at the Max-Planck Institute in Potsdam in 2009. Since 2021, he is a Vice President of the German Research Foundation (DFG) and since 2023 the Founding Director of the Center for the Transformation of Chemistry (CTC) that received initial funding of €1.25 billion. His research spanning topics from engineering to immunology has been documented in >670 journal articles and >60 patents was recognized with >40 international awards. Peter Seeberger supports open access publishing as the Editor-in-Chief of the Beilstein Journal of Organic Chemistry. He is a co-founder of the Tesfa-Ilg Foundation that works in Ethiopia and nine successful companies.
Institute of Chemistry and Technology of Biobased Systems, Graz University of Technology, Austria
Tanja M. Wrodnigg received her Ph.D. in 1999 at Graz University of Technology in Austria in the field of Glycochemistry supervised by Arnold E. Stütz. From 2001 – 2003 she joined Prof. Stephen Withers at UBS in Vancouver University of British Columbis where she worked on the synthesis for glycosynthases and their biological investigation. Back in Austria she started her independent career at the Institute of Organic Chemistry and in 2008 she received her Habilitation in Organic Chemistry, Glycochemistry. In 2020 Tanja was appointed as full professor for Glycochemistry at Graz University of Technology and established the Institute for Chemistry and Technology of Biobased Systems at TU Graz. Research interest is the design of efficient and concise synthetic approach of biological active glycomimetics, carbohydrate processing enzyme inhibitors, probes for activity based protein profiling, lectin ligands, biological active materials, method development for polysaccharides modification.
Invited Speakers
Laboratório de Química Orgânica e Farmacêutica, Departamento de Ciências, Químicas, Faculdade de Farmácia, Universidade do Porto, Portugal
Discovering New Antimicrobial Drugs in a Holistic One Health Approach
Centro de Química Estrutural, Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Portugal
Synthesis of novel D-glucuronamide-based nucleosides and nucleos(t)ide analogs with anticancer and antibacterial potential
Nuno Manuel Xavier received a double PhD degree in Chemistry (Organic Chemistry) from the University of Lisbon and from the National Institute of Applied Sciences of Lyon (2011). He was afterwards a Postdoctoral Research Fellow at the University of Natural Resources and Life Sciences of Vienna and then at Faculty of Sciences, University of Lisbon (FCUL). He started his independent career at FCUL in 2014 with an Investigator Starting Grant, stablishing his research lines in the context of Medicinal Chemistry of Nucleos(t)ides. Since 2020 he is Assistant Researcher at Centro de Química Estrutural, FCUL. His research interests encompass the development of structurally novel nucleos(t)ide analogs of potential therapeutic interest.
Senior Staff Researcher - Institute of Parasitology and Biomedicine López Neyra – CSIC, Spain
DNA G-quadruplex ligands as potent anticancer and anti-infective agents
Juan Carlos is Senior Staff Researcher at the Institute of Parasitology and Biomedicine López Neyra (CSIC), and is Founder and Scientific Advisor of Limnopharma, a start-up focused in the development of new therapeutics for ophthalmic diseases. His research started in the bioorganic and food chemistry areas. His laboratory is currently focused on the area of medicinal chemistry working on the design and synthesis of drugs based on phenolic natural products for the treatment of neurodegenerative and retinal degenerative diseases, and on DNA quadruplex ligands as anticancer and anti-infective agents. He is author of more than 100 papers and inventor of 12 patents.
Department of Chemistry and Pharmacy, Friedrich-Alexander University of Erlangen-Nürnberg, Germany
Multi-Step Domino Reactions: Facile Access to Bioactive Compounds for Life Sciences
Svetlana B. Tsogoeva graduated with Distinction from St. Petersburg State University, where she completed her doctoral thesis supported by Procter & Gamble. After postdoctoral research at Johann Wolfgang Goethe University, Frankfurt am Main, Germany, she joined in July 2000 the Degussa AG Fine Chemicals Division. She was appointed in January 2002 as the first Junior Professor in Germany at the Georg-August-University of Göttingen, and in February 2007, as a Professor of Organic Chemistry at the Friedrich-Alexander University of Erlangen-Nürnberg, Germany. Her research spans topics from catalysis to medicinal chemistry. She is an Editorial/Advisory Board Member for ACS Med. Chem. Lett, Pharmaceuticals, Scientific Reports, and ChemPhysChem, and recently, she has been appointed as the new Senior Editor for ACS Central Science.
Theranostic radiopharmaceuticals in nuclear medicine
Irina Velikyan is an Associate Professor in Biomedical Radiation Sciences, Uppsala University, and a Senior Scientist at PET Centre, Uppsala University Hospital, Sweden. Born in Yerevan, Armenia she graduated from Yerevan State University (Diploma with honours, 1988). She received her PhD from Uppsala University, Sweden (2005). The focus of her scientific activity is development and clinical implementation of positron emission tomography radiopharmaceuticals for molecular diagnostic imaging and quantification as well as bridging molecular imaging and therapy for personalized patient treatment. Irina has over 150 scientific publications, books, book chapters, and patents. She teaches students in nuclear medicine and radiopharmaceutical courses and supervises diploma and PhD studies at Uppsala University. She is a member of editorial boards, editor-in-chief, and manuscript reviewer of radiopharmaceutical sciences related publications.
Psilocybin can reduce pain-like behaviour in mice and potentiate the effect of gold standard treatment
Maria completed her undergraduate degree in pharmacy at the University Magna Graecia in Italy and then received a studentship from the European Union to conduct a PhD at the University of Calabria studying the involvement of autophagy in rodent models of neuropathic pain. After completing her PhD, she was working as Researcher co-investigator on an MRC grant to test the analgesic properties of novel Botulinum constructs in different models of chronic pain in mice. In 2017 she received the IASP Early Career Research Grant to expand her research on autophagy and pain and in 2019 she was awarded a Rosetrees Trust grant to explore the role of autophagy in chemotherapy-induced pain. In March 2020 she was appointed to a Lectureship in Pharmacology at the University of Reading where her research group focusses on understanding the molecular mechanisms underlying chronic pain states. In 2022 she was awarded a Springboard Fellowship (Academy of Medical Sciences) to test the analgesic properties of psychedelic drugs in preclinical models of human pain.
Université Claude Bernard Lyon 1,
UMR CNRS 5246 - ICBMS - Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires,
COSSBA team
From TPIs to KIs, some examples of the fight against cancer and some CNS diseases.
Thierry obtained a PhD in Organic Chemistry in 2002, during which he developed synthetic methodologies using palladium-catalysed key steps. Then, he joined the group of Pr. Peter Kündig in Geneva as a post-doctoral researcher, working on dessymetrisation reactions of naphtalene Cr(CO)3 complexes. He went back to France in 2004 and became assistant professor at the faculty of Pharmacy of Lyon (ISPB) in 2005. He obtained his research habilitation in 2010 and was promoted as a full Professor of Medicinal Chemistry in 2016. Trained in synthesis methodology, organometallic chemistry and asymmetric synthesis, Thierry has developed research themes in medicinal and bioorganic chemistries, since joining the faculty of Pharmacy. Different approaches combining pharmacomodulation and biophysical techniques allowed him to develop molecules of therapeutic interest in cancerology (Kinases Inhibitors, Tubulin Polymerisation Inhibitors, anti-chemoreversal agents targeting the Multi Drug Resistance phenotype), and in infectiology, targeting bacterial or viral proteins. Thierry is also the leader of COSSBA team (COnception & Synthesis of Biologically active Substances), created in 2021.
Pharmacological modulation of the stress axis for the management of persistent pain
Sandrine Géranton first studied organic chemistry and biochemistry at the “Ecole Nationale Supérieure de Chimie de Montpellier” in France. After a PhD in Pharmacology, Sandrine went on learning about pain mechanisms as a post-doctoral researcher with the London Pain Consortium at UCL, where she is now Associate Professor in molecular neuroscience. Sandrine has always been keen on applying her multidisciplinary background to further her understanding of the molecular mechanisms of chronic pain and she has been at the forefront of the investigation of the role of epigenetic mechanisms in this context. Her lab is currently focusing on elucidating the interactions between stress and pain. https://profiles.ucl.ac.uk/10207 https://www.ucl.ac.uk/biosciences/medawar-pain-and-somatosensory-labs
Honorary Guest
Dr. Jean Jacques Vanden Eynde
Former Head of the Department of Organic Chemistry, University of Mons-UMONS, Belgium
Pharmaceuticals: What has happened since 2004?
Registration
In-Person Registration
The conference will be held fully in person; it is not possible to participate online. The registration fee includes attendance at all conference sessions, morning/afternoon coffee breaks, lunches, a conference bag, and a program book. You need to register to the Conference dinner if you plan to attend. Participation in the conference is considered final only once the registration fees have been paid. The number of participants is limited: once the number of paid registrations reaches the maximum number of participants, unpaid registrations will be canceled.
When registering, please provide us with your institutional email address. This will accelerate the registration process.
Important Information
Please note that abstract submission and conference registration are two separate processes. During registration, please provide us with the same email address you used to submit your abstract(s). Otherwise, leave us a comment in the registration form, providing the email address used during the submission process. In addition, please use your institutional email address for both processes.
In order to finalize the scientific program in due time, at least one registration by any of the authors, denoted as the Covering Author, is required to cover the presentation and publication of any accepted abstract. The Covering Author registration deadline is 21 October 2024. Your abstract will be withdrawn if your registration is not complete by this date.
Participants of the event will be able to download an electronic Certificate of Attendance by accessing their dashboards on Sciforum.net once the event is concluded. The certificates will be found under the "My Certificates" category.
Group Registration: Groups of five or more attendees are offered a 10% discount on the registration fees. To enjoy this discount, you need to complete one multiple registration by selecting the number of people attending in each category (type of registration) during the first step of the registration process. Please note that no other discounts will be applicable.
Certificate of Attendance: Participants of the event will be able to download an electronic Certificate of Attendance by accessing their dashboards on Sciforum.net once the event is concluded. The certificates will be found under the "My Certificates" category.
Reduced fees
If you are affiliated with a university in a low- or middle-income country, you are automatically eligible for a price reduction. However, please note that the reduced price will only be added to your registration when it is processed. This means that you do not have to pay the stated price immediately upon registration, and you will receive an invoice with the price adjustment after you have registered. Below, you can find the list of low- and middle-income countries.
Registration Fees
|
Early Bird Until 9th October 2024 |
Regular Until 20th November 2024 |
Supported documents | |
|---|---|---|---|
| Academic – Research Institutions | 500.00 EUR | 600.00 EUR | |
| Early Career Researcher (PhD completed within the past five years) | 350.00 EUR | 450.00 EUR |
Please include a proof of graduation date (Diploma, University profile page screenshot, etc.) |
| Student | 300.00 EUR | 400.00 EUR |
Scanned copy or photograph of your current student ID is required. |
| Topical Advisory Panel/Guest Editor/Board Member of Pharmaceuticals | 400.00 EUR | 500.00 EUR | |
| Non-Academic | 800.00 EUR | 900.00 EUR |
| Start date - End date | Price | |
|---|---|---|
| Conference Dinner | 2nd July 2024-20th November 2024 | 60.00 EUR |
Free Registration Options
| Chairs, Invited Speakers, MDPI Guests |
Active discounts
Group of 5: 10% discount
Note: Group size refers to the number of registered attendees in the same registration order.
Cancellation policy
| Cancellation of paid registration is possible under the terms listed below: | |
| > 2 months before the conference | Full refund but 60 EUR is retained for administration |
| > 1 month before the conference | Refund 50% of the applying fees |
| > 2 weeks before the conference | Refund 25% of the applying fees |
| < 2 weeks before the conference | No refund |
Disclaimer
In the unlikely event that MDPI deems it necessary to cancel the conference, all pre-paid registration fees will be reimbursed. MDPI shall not be liable for reimbursing the cost of travel or accommodation arrangements made by individual delegates.
Beware of unauthorized registration and hotel solicitations
Note that Sciforum is the only official registration platform to register to Pharmaceuticals 2024 and that we are not associated with any hotel agency. While other hotel resellers and travel agencies may contact you with offers for your trip, they are not endorsed by or affiliated with Pharmaceuticals 2024 or Sciforum. Beware that entering into financial agreements with non-endorsed companies can have costly consequences.
Insurance
The organizers do not accept liability for personal accident, loss, or damage to private property incurred as a result of participation in Pharmaceuticals 2024. Delegates are advised to arrange appropriate insurance to cover travel, cancellation costs, medical, and theft or damage of belongings.
MDPI Conference Admissions Policy
- All registered conference delegates are asked to always wear their badges throughout the conference.
- Conference sessions, the catering area, and the poster area are solely restricted to badge holders. Any person attending these areas without a badge will be asked to leave the premises.
- Badge holders must not allow their badges to be worn by anyone else. Any failure to do so is likely to lead to the badge holder and the person wearing the badge being removed from the premises.
- Press badges are restricted to publishers, editors, journalists, broadcasters, and web bloggers associated with the conference subject area. Members of the press may be asked to produce accreditation in the form of a photocopy of a recognized press or media card, a business card, a letter from the editor, or an official web address linking to a press release in order to verify their position.
- Photographs and videos may be taken during the conference. Anyone attending the conference consents to such photography and filming without compensation and confirms that the organizers shall be entitled to use such photographs and videos, which may include photographs and videos of visitors, for the purpose of marketing the conference in the future and for exploitation in any and all media, without liability.
Payment methods
Wire transfer, Credit card
Currencies accepted by this event
Swiss francs (CHF) , Euros (EUR) , US dollars (USD) , Pounds sterling (GBP) , Japanese yen (JPY) , Canadian dollars (CAD) and Singapore dollars (SGD)
Conference Dinner
We are excited to announce that the Conference Dinner will be held at the prestigious Gallery Hotel, located in the heart of Barcelona. Enjoy a delightful evening in a vibrant setting next to iconic landmarks such as La Pedrera, Passeig de Gràcia, Casa Batlló, and Plaça Catalunya.
Time: 28 November 2024, 20.30h
Location: Gallery Hotel. C/ del Rosselló, 249, 08008 Barcelona
Menu: 60€
Main course options: meat, fish or vegetarian
Please let us know in your registration your main course preference and any allergies or relevant dietary restrictions.
Join us for an unforgettable dining experience in one of Barcelona's most renowned locations. We look forward to seeing you there!
Abridged Program
Wednesday 27th November 2024: From 12:00 to 18:30
Thursday 28th November 2024: From 9:00 to 18:30 (Conference dinner at 20:30)
Friday 29th November 2024: From 9:00 to 16:30
Detailed Program
Day 1 — Wednesday, 27 November 2024
|
12:00–14:00 |
Check-In |
|
|
14:00–14:15 |
Opening Ceremony |
|
|
S6. Computer Aided Drug Design Chaired by Amelia Pilar Rauter |
||
|
14:15–15:05 |
Jesús Jiménez Barbero Plenary Speaker |
Breaking the limits in understanding glycan recognition by NMR |
|
15:05–15:35 |
Thierry Lomberget Invited Speaker |
From TPIs to KIs, some examples of the fight against cancer and some CNS diseases. |
|
15:35–15:50 |
Alžběta Zemánková |
The Design of Drug Delivery Systems for Low Bioavailability Drugs via Compatibility Modeling: The Case of Paclitaxel |
|
15:50–17:00 |
Coffee Break & Poster Session A |
|
|
S8. Natural Products as a Source of Drugs (Part I) Chaired by Mary Jane Meegan |
||
|
17:00–17:30 |
Maria Emilia Sousa Invited Speaker |
Discovering New Antimicrobial Drugs in a Holistic One Health Approach |
|
17:30–17:45 |
Sarah Bouameur |
Enhanced sunscreen liniment with hematite nanoparticles for efficient photoprotection |
|
17:45–18:00 |
Sharmin Sultana |
Identification and Quantification of Isoflavones in Monofloral Clover Honeys |
|
18:00–18:15 |
Annachiara Fioccardi |
Morella spathulata (Myricaceae) as a source of antioxidants and anti-inflammatory compounds for traditional medicine in Madagascar |
|
18:15–18:30 |
Flash Presentations |
Daniel Chen Azizah Malebari Paschalina Chatzopoulou |
Day 2 — Thursday, 28 November 2024
|
S7. Synthetic Chemistry and Drug Discovery (Part I) Chaired by Joachim Jose |
||
|
9:00–9:50 |
Peter Seeberger Plenary Speaker |
Structurally-defined Glycans as Basis for Diagnostics, Vaccines and Therapeutics |
|
9:50–10:20 |
Juan Carlos Morales Invited Speaker |
DNA G-quadruplex ligands with potent antiparasitic and antibiotic activity |
|
10:20–10:35 |
Zsófia Szász |
Targeting Pancreatic Tumour Cell Line: Characterization of the Anti-Tumour Effects of Fluorinated ONC201 Analogues |
|
10:35–11:05 |
Coffee Break |
|
|
S7. Synthetic Chemistry and Drug Discovery (Part II) Chaired by Nuno Manuel Xavier |
||
|
11:05–11:35 |
Svetlana Tsogoeva Invited Speaker |
Multi-Step Domino Reactions: Facile Access to Bioactive Compounds for Life Sciences |
|
11:35–11:50 |
Luisa Camerin |
Photoswitchable carbamazepine analogs for non-invasive neuroinhibition in vivo |
|
11:50–12:05 |
Amgad Albohy |
Studies on the Design of Tropomyosin Receptor Kinase A (TrkA) Inhibitors: A Quick Snippet from Our Lab |
|
12:05–12:20 |
Jennifer Szilagyi |
Synthesis of novel potentially bioactive guanidino- and guanidinopurine-containing nucleoside analogs |
|
12:20–12:35 |
Diogo Boreski |
Design and synthesis of new boron-based N-acylhydrazones as potential anti-trypanosomal agents |
|
12:35–14:30 |
Lunch Break & Poster Session B & Group Photo |
|
|
S4. Immunity and Inflammation S8. Natural Products as a Source of Drugs (Part II) Chaired by Maria Emília Sousa |
||
|
14:30–15:00 |
Irina Velikyan Invited Speaker |
(Radio)Theranostic radiopharmaceuticals in nuclear medicine |
|
15:00–15:15 |
Naiha Mehmood |
Reversal of Nickel Oxide Nanoparticle Genotoxicity in Rat Livers and Kidneys by Vitamin C |
|
15:15–15:30 |
Maria Dolores Salinas Hidalgo |
Peptide-mediated inhibition of pericyte chaperone-mediated autophagy reveals an effective treatment against glioblastoma progression |
|
15:30–15:45 |
Catarina Maria |
Synthesis of New Gram-Negative Peptidoglycan Mimetics to Overcome Antimicrobial Resistance |
|
15:45–16:00 |
Ana Margarida |
Unlocking Nature's Potential: Anticoagulant and Cytotoxic Effects of Sericin and Chelidonium majus L. |
|
16:00–16:15 |
Lyubomira Radeva |
Improvement of the antioxidant effects of resveratrol via encapsulation in biopolymeric nanogels |
|
16:15–16:30 |
Flash Presentations |
Bubueanu Elena Corina Tânia Moreira |
|
16:30–17:00 |
Coffee Break |
|
|
17:00–18:30 |
Round Table: The Challenge of Communicating Science |
|
|
18:30-19:30 |
EBM Meeting |
|
|
20:30–22:30 |
Conference Dinner |
|
Day 3 — Friday, 29 November 2024
|
S1. Neurodegeneration Chaired by Jesús Jiménez-Barbero |
||
|
9:00–9:50 |
Tanja M. Wrodnigg Plenary Speaker |
Glycomimetics: Useful Tools and Potential Therapeutics |
|
9:50–10:05 |
Angelina Ivanova |
A Novel Enzymatic Approach for A Dandruff Treatment: Targeted Fungal Growth Inhibitors |
|
10:05–10:20 |
Thangavel Muthusamy |
Neuroprotective Effect Of Oxidative Damage By Boerhaavia Diffusa L. Against Neurotoxic Agents In Rat Brain Homogenate |
|
10:20–10:35 |
Nesrine Hagui |
A Therapeutic approach to antibiotics at the trauma center and major burns |
|
10:35–10:50 |
Rosanna Martinelli |
Molecular Characterization of Therapeutic Properties of Couroupita Guianensis Bark Decoction used in Traditional Shamanic Medicine. |
| 10:50-10:55 |
Flash Presentations |
Bissera Pilicheva |
|
11:00–11:30 |
Coffee Break |
|
|
S2. Pain Care and Aging chaired by Gary Stephens |
||
|
11:30–12:00 |
Sandrine Geranton Invited Speaker |
Pharmacological modulation of the stress axis for the management of persistent pain |
|
12:00–12:30 |
Maria Maiarú Invited Speaker |
Psychedelics - A New Frontier For Chronic Pain Treatment |
|
12:30–12:45 |
Lydia Tidmarsh |
A Neurochemical, neurofunctional and psychological assessment of the emergence of chronic pain with long-COVID |
|
12:45–13:00 |
Wiem Guibane |
Qualitative Audit of Pain Care Ethics Practices in a Trauma and Burn Center |
|
13:00–14:30 |
Lunch Break |
|
|
S5. Bioorganic Molecules chaired by Amelia Pilar Rauter |
||
|
14:30–15:00 |
Nuno Xavier Invited Speaker |
Synthesis of Novel D-Glucuronamide-based Nucleosides and Nucleos(t)ide Analogs with Anticancer and Antibacterial Potentia |
|
15:00–15:15 |
Petr Snetkov |
In Vitro Antibacterial Activity of Mangiferin-Loaded Polymer Films Based on Hyaluronic Acid |
|
15:15–15:30 |
Plamen Zagorchev |
Laser-activated magnetic-assisted delivery of bioactives using iron oxide nanoparticles: a biological perspective |
|
15:30–15:35 |
Flash Presentation |
Gabriela Hrčková |
|
15:35–16:00 |
Award Ceremony and Closing Remarks |
|
Poster Sessions
The posters have been divided into two groups and will be presented in one of the two poster sessions.
Poster Session A
Posters: A1 – A17
Wednesday, 27 November 2024 (15:30–17:00)
Posters should be set up on Wednesday morning and must be removed by 18:30 on the same day.
Poster Session B
Posters: B1 – B17
Thursday, 28 November 2024 (12:30–14:30)
Posters should be set up on Thursday morning and must be removed by 18:30 on the same day.
Each presenter will be provided with a vertical poster board. Note that the maximum poster size limited to A0:
- 84 x 120 cm / 33 x 47 in (width x height)
- in vertical orientation (portrait)
Please print your poster prior to the conference.
The session for each poster, along with the poster numbers, titles, and presenting author, can be found below. Please contact us if the poster presenter's name is incorrect in this list.
By clicking on the icon below, you can view and download the list of posters (updated 11.11.2024)
Book of Abstracts
Event Awards
In order to recognize the works presented during the conference in the format of posters and presentations, two awards will be offered to our conference participants, sponsored by the journal Pharmaceuticals. The award winners will be selected by the Chairs and Scientific Committee after evaluation of all selected talks and posters presented at the conference.
We will be offering the following two awards to our conference attendees:
The Awards
Number of Awards Available: 1
Prize: EUR 500
Number of Awards Available: 1
Prize: EUR 300
Venue, Travel and Accommodation
Venue
Barcelona
Barcelona is the capital and largest city of Catalonia and is Spain's second-largest city, with a population of over one and a half million people.
Located on the northeastern Mediterranean coast of Spain, this city has a rich and diverse history, with its roots dating back to Roman times. The fruitful medieval period established Barcelona's position as the economic and political center of the Western Mediterranean. The city's Gothic Quarter bears witness to the splendor enjoyed by the city from the 13th to the 15th centuries.
The 20th century ushered in widespread urban renewal throughout Barcelona city, culminating in its landmark Eixample district, which showcases some of Barcelona's most distinctive Catalan art-nouveau, or modernista, buildings. The Catalan Antoni Gaudí, one of the most eminent architects, designed buildings such as La Pedrera, the Casa Batlló, and the Sagrada Família church, which have become world-famous landmarks.
In 1992, Barcelona gained international recognition by hosting the Olympic games, which brought about a massive upturn in its tourism industry. For visitors, this has translated into the very modern yet incredibly old city you see now in the 21st century, where new elements work to both preserve and celebrate the city’s heritage and origins.
Barcelona has plenty of outdoor markets, restaurants, shops, museums, and churches. The city is also very walkable, with an extensive and reliable Metro system for more far-flung destinations.
Casa Convalescència
Travel
By plane:
The international airport of Barcelona is called Barcelona-El Prat and is located 10 km from the city center. The airport is well connected to airport hubs in Europe and several locations around the world. For more information about the airport and flights, please visit the official website at https://www.aena.es.
Once you get to the airport, you have several options to reach the city center.
To the city center:
-
By shuttle bus: AEROBUS (https://aerobusbarcelona.es). This bus connects Barcelona Airport (Terminal 1 and Terminal 2) with the city center (Pl. Espanya / Pl. Catalunya) in 35 minutes. It runs every day of the year with departures every 5 minutes and costs EUR 6.75.
-
By train: TRAIN R2 NORD (https://rodalies.gencat.cat). This train connects Terminal 2 of the airport with the city center (Barcelona–Passeig de Gràcia). It runs every day of the year with departures every 30 minutes and costs EUR 4.60.
-
By taxi: Taxis just outside the arrival area. The taxi from the airport to the city center (Plaza Catalunya) costs approximately EUR 30–35. Public taxis in Barcelona can charge four types of fares. These fares must be visible inside the taxi and are usually printed on a sticker over the window. Finally, the amount payable must be indicated on the taximeter. VTC apps that work in Barcelona are Bolt and Cabify and might offer cheaper rates.
To the conference venue:
-
By train: TRAIN R2 NORD (https://rodalies.gencat.cat). You should get off at “Barcelona Sants” station. From there, you can take METRO L5 (get off at Sant Pau | Dos de Maig). Alternatively, you may take a taxi just outside the station. The train from the airport costs EUR 4.60, and the metro costs EUR 2.55. You can buy the tickets at the train station and metro stops, respectively. The taxi from the train station to the conference venue costs about EUR 10.
-
By metro: LINE L9 (https://www.tmb.cat). This metro line connects Barcelona Airport (Terminal 1 and Terminal 2) with the city (get off at Collblanc). From here, you can take METRO L5 (get off at Sant Pau | Dos de Maig). The metro from the airport costs EUR 5,50 and the city metro EUR 2,55.
-
By taxi: Taxis just outside the arrival area. The taxi from the airport to the conference venue costs approximately EUR 30–35. VTC apps that work in Barcelona are Bolt and Cabify and might offer cheaper rates.
By train:
Barcelona Sants station is Barcelona's largest train station and provides rail services both in and around Barcelona and for the whole of Spain and beyond. For more information about the station and train service, please visit the official website at https://www.renfe.com.
Once you get to the station, you have the following options to reach the conference venue:
-
By metro: LINE L5 (https://www.tmb.cat).
-
By taxi: Taxis just outside the station. The taxi from the station to the conference venue costs about EUR 10.
Accommodation
We want your stay in Barcelona during the conference to be as comfortable as possible. With that in mind, we have agreed on a discount with several hotels to make your choice of accommodations easier. Please book your accommodation online and contact the hotels directly with any issues or requests related to accommodation bookings.
We are delighted to announce that the following hotels will offer a discounted price for all Pharmaceuticals 2024 attendees:
Hotel |
Description |
How to book |
|
|
Located a few streets away from the Sagrada Familia, in a central neighbourhood and just 15 minutes on foot from the conference venue. |
Click below to make a reservation with a 10% discount in one of their three hotels (Atenas, Sagrada Familia and Albeniz) or use the code "CATALONIABCN".
|
|
|
Located by the gardens of Baix Guinardó, just a few streets away from the Sagrada Familia and 15 minutes on foot from the conference venue. |
Click below to make your booking and add the 10% discount code ‘MDPI24’.
|
|
|
Centrally located, modern, comfortable, with impressive views of the Sagrada Familia and just 15 minutes walking distance from the conference venue. |
Click below to make your booking and add the 5% discount code ‘PHARMA2024’.
|
|
|
The Social Hub Barcelona is situated in the lively Poblenou district and welcomes digital nomads, students, and travelers. Its unique community-focused concept merges a boutique hotel, student and extended-stay rooms, a restaurant, a coworking space, a bar, a gym, terraces, solariums, and a Rooftop Bar and pool with panoramic city views. It is 30–35 minutes away (by metro or bus) from the conference venue. |
Click below to make your booking and add the 10% discount code ‘MDPI24’.
|
|
|
Oriente Atiram and Meson Castilla Atiram: Located in Las Ramblas, they have a fantastic central location next to Plaza Catalunya and the famous Boqueria market, 20–25 minutes away (by metro) from the conference venue. Arenas Atiram: The Arenas Atiram Hotel offers a highly personalized service together with very friendly, elegant facilities, 30–40 minutes away (by metro or bus) from the conference venue. Tres Torres Atiram: Located in the center of one of Barcelona's best residential neighborhoods, next to the distinguished commercial and leisure districts, Diagonal Avenue, it is 30–40 minutes away (by metro or bus) from the conference venue. |
Click below to make your booking and add the 10% discount code ‘MDPI24’.
|
These accommodations have been carefully chosen to provide comfort and convenience for our guests while ensuring affordability through negotiated rates. Prepare to make the most of your conference experience with our exclusive lodging options designed to enhance your stay.
Beware of Unauthorized Registration and Hotel Solicitations
Note that Sciforum is the only official registration platform to register to Pharmaceuticals 2024 and that we are not associated with any hotel agency (other than those listed above). While other hotel resellers and travel agencies may contact you with offers for your trip, they are not endorsed by or affiliated with Pharmaceutical 2024 or Sciforum. Beware that entering into financial agreements with non-endorsed companies can have costly consequences.
Instructions for Authors
Pharmaceuticals 2024 will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference. Moreover, participants will have the opportunity to contribute a full manuscript to a Special Issue related to the conference in the open-access journal Pharmaceuticals.
The conference will be held fully in person; it is not possible to participate online. Please note that abstract submission and conference registration are two separate processes. Please use your institutional email address for both processes.
- Create an account on Sciforum if you do not have one, then click on ‘New Submission’ in the upper-right corner of the window; or, click on ‘Submit Abstract’ at the top of this webpage.
- Choose a session that is best suited for your research.
- Submit an abstract in English—the word limits are a minimum of 150 words and a maximum of 300 words.
- The deadline to submit your abstract is 6 September 2024. You will be notified about its acceptance by 4 October 2024.
- Upon submission, you can select if you wish to be considered for oral or poster presentation (or both). Following assessment by the Chairs and Scientific Committee, you will be notified by 4 October 2024 whether your contribution has been accepted for oral or poster presentation.
- Please note that, in order to finalize the scientific program in due time, at least one registration by any of the authors, denoted as Covering Author, is required to cover the presentation and publication of any accepted abstract. Covering Author registration deadline is 21 October 2024. Your abstract will be withdrawn if your registration is not complete by this date.
- Invited talks will be 30 minutes long, including questions (25 minutes oral presentation + 5 minutes Q&A).
- Short talks will be 15 minutes long, including questions (10 minutes oral presentation + 5 minutes Q&A).
- Please ensure that your slides are formatted in widescreen (16:9) aspect ratio.
- Each presenter will be provided with a vertical poster board. Maximum poster size is limited to A0: 84 x 120 cm / 33 x 47 in (width x height) in the vertical orientation (portrait). Please print your poster prior to the conference. A plan for the poster session will be circulated later.
-
All accepted abstracts will be available online in Open Access form on Sciforum.net during and after the conference.
- Participants of this conference are cordially invited to contribute with a full manuscript to the Special Issue related to the conference called "Pharmaceuticals 2024—Recent Advances in Pharmaceutical Sciences Towards a Healthy Life", in the journal Pharmaceuticals, with a 20% discount on the publication fees. Please note that no other discounts will be applicable.
- Pharmaceuticals is indexed within SCIE (Web of Science), Scopus, PubMed, and other databases. The 2023 Impact Factor for Pharmaceuticals is 4.3, ranking Q1 (69/354) in “Pharmacology & Pharmacy” and Q2 (20/72) in “Chemistry, Medicinal”.
Visa Information
Please note that you must apply for your own visa application. MDPI is not responsible for any visa application. However, MDPI can provide a Visa Support Letter. To be eligible for such a document, the criteria below must be fulfilled.
Visa Support Letter
- Applicants must have paid for registration and submitted an abstract in order to get a letter of support.
- Applicants must provide us with a scan of their valid, in-date passport that contains a photo of them.
- Applicants must provide us with an academic CV, two references from their institution (contact information including institutional email and phone), and a letter of support from their institution to confirm that they support the delegate attending the meeting.
- This must be carried out in good time before the meeting; “last minute” requests will not be processed.
More useful information on visa application
Event Gallery
Sponsors and Partners
Find all information on sponsorship opportunities in our Sponsorship Agenda. If you have any questions or wish to discuss options further, please do not hesitate to contact us at pharmaceuticals2024@mdpi.com.
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Partnering Societies
Media Partners
